The Novel CXCR4 Antagonist KRH-3955 Is an Orally Bioavailable and Extremely Potent Inhibitor of Human Immunodeficiency Virus Type 1 Infection: Comparative Studies with AMD3100

The previously reported CXCR4 antagonist KRH-1636 was a potent and selective inhibitor of CXCR4-using (X4) human immunodeficiency virus type 1 (HIV-1) but could not be further developed as an anti-HIV-1 agent because of its poor oral bioavailability. Newly developed KRH-3955 is a KRH-1636 derivative...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Murakami, Tsutomu, Kumakura, Sei, Yamazaki, Toru, Tanaka, Reiko, Hamatake, Makiko, Okuma, Kazu, Huang, Wei, Toma, Jonathan, Komano, Jun, Yanaka, Mikiro, Tanaka, Yuetsu, Yamamoto, Naoki
Formato: Artigo
Idioma:Inglês
Publicado em: American Society for Microbiology (ASM) 2009
Assuntos:
Antiviral Agents
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2704660/
https://ncbi.nlm.nih.gov/pubmed/19451305
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.01727-08
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados